Telo Genomics Stock

Telo Genomics Equity

The The Equity of Telo Genomics (TELO.V) as of Aug 25, 2026 is 515,000.00 CAD.

Equity

515,000.00CAD

Last updated:

In 2026, Telo Genomics's equity was 515,000.00 CAD, a % increase from the 0.00 CAD equity in the previous year.

The Telo Genomics Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2016
-204,900.00 CAD
Jan 1, 2017
2.23 M CAD
Jan 1, 2018
-314,000.00 CAD
Jan 1, 2019
-1.04 M CAD
Jan 1, 2020
775,300.00 CAD
Jan 1, 2021
3.69 M CAD
Jan 1, 2022
2.60 M CAD
Jan 1, 2025
515,000.00 CAD
The Telo Genomics Equity history
YEAREquityYoY
515,000.00CAD-80.22%
2.60 MCAD-29.37%
3.69 MCAD+375.38%
775,300.00CAD-174.20%
-1.04 MCAD+232.77%
-314,000.00CAD-114.10%
2.23 MCAD-1,186.63%
-204,900.00CAD-136.17%
566,500.00CAD+25.89%
450,000.00CAD—
Access this data via the Eulerpool API
Get Free API Key

Telo Genomics Stock analysis

What does Telo Genomics do? Telo Genomics is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Telo Genomics's Equity

Telo Genomics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Telo Genomics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Telo Genomics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Telo Genomics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Telo Genomics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Telo Genomics stock

The Equity of Telo Genomics is 515,000.00 CAD in 2026.

On Eulerpool you can find the complete historical development of The Equity Telo Genomics since 2006 – with annual values, charts, and detailed analysis.

The Equity's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Telo Genomics historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Telo Genomics

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Telo Genomics